Sitagliptin and Metformin Hydrochloride Tablets, 50 mg/500 mg and 50 mg/1000 mg are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus
The Product is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Xalatan
The first and only immuno-oncology drug approved for the treatment of nasopharyngeal carcinoma
The product will be manufactured at Lupin’s Somerset facility in the US
This product will be manufactured at Lupin’s Nagpur facility in India
Fludrocortisone acetate tablets will be produced at the Group's manufacturing site at Moraiya, Ahmedabad
Paliperidone extended-release tablets will be produced at the Group’s manufacturing site at SEZ, Ahmedabad
Approval is based on Phase III INAVO120 results, showing the Itovebi (inavolisib)-based regimen more than doubled progression-free survival compared with palbociclib and fulvestrant alone in the first-line setting
Mylan and Novo Nordisk reach settlement of US patent litigation related to Ozempic
Enzalutamide Tablets will be produced at the Group’s manufacturing site at SEZ, Ahmedabad
Subscribe To Our Newsletter & Stay Updated
